trending Market Intelligence /marketintelligence/en/news-insights/trending/tI2SorxW6zTuHsqRr5ev3Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Celgene seeks EU approval for multiple sclerosis therapy

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Celgene seeks EU approval for multiple sclerosis therapy

Celgene Corp. submitted a marketing authorization application to the European Medicines Agency for its drug ozanimod to treat a disease affecting the central nervous system.

The Summit, N.J.-based biopharmaceutical company is seeking approval for ozanimod in treating adults with relapsing-remitting multiple sclerosis, or disease that alternates between symptoms worsening and disappearing. Multiple sclerosis is a potentially disabling nervous system disease that affects the communication of information between the brain and the body.

The application is based on late-stage studies known as Sunbeam and Radiance, which evaluated the effectiveness and safety of ozanimod.

Celgene said it remains on track to submit a new drug application to the U.S. Food and Drug Administration for relapsing forms of multiple sclerosis by the end of March. Ozanimod, which has been framed as one of the next big revenue drivers for Celgene, was rejected by the FDA in February 2018 — a decision that came as a surprise to company executives.

Ozanimod is an investigational compound that has yet to receive approval in any territory. The drug is being developed for immune-inflammatory indications including ulcerative colitis and Crohn's disease — two types of inflammatory bowel diseases.